A study from the Georgia Lupus Registry shows that systemic lupus erythematosus patients are at greatest risk for cardiovascular disease events between years 2 and 11 after diagnosis and higher in Black people or those with a discoid rash.
Dr. John Cush RheumNow
4 years ago
NEJM: 70 yoWM w/ 3-wk temporal headaches, jaw pain with chewing, temporal artery tender and thickened, but NO vision Sxs. a 15, CRP 24 mg/L. and Doppler US showed “halo sign” . Temp art Bx confirmed the Dx of GCA https://t.co/mIUA8pMh2l https://t.co/o50MkidinC
Dr. John Cush RheumNow
4 years ago
J Rheum review shows 4,444 rheums in 2015 & 3,547 in 2020 recv some sort of pharma payments (There are ~5000 US Rheums). Pandemic drops affected travel, etc (98%), speaking (72%), meals (72%), but less consulting (23%) https://t.co/2UMqp4XDhJ https://t.co/dHtHUBO1Wk
Dr. John Cush RheumNow
4 years ago
Downstream revenues from Rheum? The Rheumatologist reports and impt reference showing for every $1 dollar office visit billed, $12.14 generated in downstream revenues (infusions, labs, surgery). Cognitive specialists are undervalued! https://t.co/YatkwrBCeQ https://t.co/OzSsxXKVhC
Dr. John Cush RheumNow
4 years ago
Review of risk factors for osteoporosis and fractures in #RA. OP Risk factors same as gen population (but more prevalent in RA) - smoking, calcium intake, vit D deficiency, hypogonadism and chronic exposure to glucocorticoids https://t.co/KsE5ag29ZN https://t.co/OQtfoKcIX2
Dr. John Cush RheumNow
4 years ago
Co-administration of MTX with Folic Acid on the same day did not reduce efficacy compared to FA application one day after MTX. (based on AIA was induced in female Lewis rats) https://t.co/gBWhjhS8Nu https://t.co/5799lleK22
The results of a treat-to-target (T2T) combination therapy trial in patients with early rheumatoid arthritis (RA) show that if patients fail to respond initially, then a second, more intensified regimen can turn initial nonresponders into responders.
Dr. John Cush RheumNow
4 years ago
Urine proteomics on 54 SLE pts in the Belimumab–Lupus Nephritis trial, compared responders (n 31) v non-responders (n 22), on BEL or SOC. Reduction in urinary CD163 was strongly associated with complete renal response @wk52 & CD23 @wk24 https://t.co/Rais8fKame https://t.co/F3B9W7u7VO
Dr. John Cush RheumNow
4 years ago
No Special Heart Risk With JAK Inhibitors, Study Finds
Patients taking JAK inhibitors for RA experienced similar cardiovascular outcomes as those using the TNF blocker adalimumab (Humira), analysis of French national registry data indicated.
https://t.co/oUt1hz88ll https://t.co/RkUUvfC4YK
Dr. John Cush RheumNow
4 years ago
Arthritis Clinical Trials Comparison Grid
https://t.co/rLxTauJqX1 https://t.co/U7i5baSNwt
Dr. John Cush RheumNow
4 years ago
Sjogrens - Dx tips, myths & mistakes:
• SS not rare; affects 1 in 400
• 95% female, but SS is more severe in men
• African Americans have a severe systemic phenotype
• Asians report dryness Sxs
• Smoking & alcohol intake often avoided by SS pts
https://t.co/B2hR7z8H5Z https://t.co/g0FKhcmoXa
The American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP) proudly recognizes the recipients of its 2022 Master of the ACR and ARP designations, ACR Awards of Distinction, and ARP Awards of Merit and Appreciation. The awards will be given to this year’s winners at ACR Convergence 2022.
Dr. John Cush RheumNow
4 years ago
Actual video of needle arthroscopy in patients w/ suspected septic arthritis. https://t.co/tWgP4ZpFBJ https://t.co/cLWM48NBlA
A prospective cohort study of treatment and pregnancy outcomes in women with RA shows that TNF inhibitor use during pregnancy did not increase the risk of adverse pregnancy outcomes, but instead led to more positive outcomes such as fewer low-birth-weight deliveries.
Dr. John Cush RheumNow
4 years ago
Biomedical researchers are at their most creative/innovative EARLY in their career. Study based on 5.6 million papers (1980 to 2009). While least innovative drop out early; in the remaining, innovativeness tends to decline over their career.https://t.co/XY5xQfY8Ba https://t.co/Cs3MUr7qIi
